Industry News Seawolf Therapeutics / Sanofi BioSpace
Seawolf Launches With $100M and a $1.2B Sanofi Deal for Redosable DNA Medicines
- Seawolf Therapeutics raised a $100M Series A from Versant, Novartis Venture Fund, Lilly, CRISPR Therapeutics and others.
- Its Trident platform delivers DNA payloads in redosable lipid nanoparticles, claimed to last longer than RNA-LNP therapies with similar potency and safety.
- Sanofi signed a multi-target research and licensing deal worth up to $1.2B in milestones plus royalties, covering bleeding disorders and other indications.
Non-viral DNA delivery that can be redosed would sidestep the immunity and dosing limits of AAV, so a Sanofi deal plus Lilly and Novartis money is a notable vote. But the support is animal data only, and the lead program and targets are undisclosed. Compare it against durable RNA-LNP editing and Sanofi's own hemophilia pipeline before reading too much into the headline figure, since milestones dwarf the upfront.
Source: BioSpace ↗ Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines